[1]Patent:WO2015/171162,2015,A1.Locationinpatent:Paragraph0029
Title: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Journal: Drugs 20170701
Title: Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20160801
Title: Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.
Journal: Drugs 20160801
Title: Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901
Title: Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Journal: The Annals of pharmacotherapy 20150501
Title: Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Journal: Expert opinion on pharmacotherapy 20150301
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology 20150101
Title: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
Journal: Journal of medicinal chemistry 20140313
Title: Hepatitis C virus NS5A: tales of a promiscuous protein.
Journal: The Journal of general virology 20040901
Title: Side effects of alpha interferon in chronic hepatitis C.
Journal: Hepatology (Baltimore, Md.) 19970901
Title: Krishnan P, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015 Feb;59(2):979-87
Title: DeGoey DA, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57